Peptide Program
Our Own Peptide Program: A Once-Monthly GLP-1
Alongside our biologics portfolio, BioFutureRx engineers novel peptide therapeutics in-house. Our lead candidate, BFRx3711, is a proprietary GLP-1 analog we designed for potential once-monthly dosing in type 2 diabetes and obesity — and we are seeking a strategic partner to help advance it toward the clinic.
Today
The limitation of today's therapies
The leading GLP-1 therapies for diabetes and obesity are given as once-weekly injections. Highly effective, but weekly dosing is an ongoing burden — and it leaves room for a meaningful improvement: less-frequent administration.
The BFRx3711 advantage
The once-monthly advantage
We engineered BFRx3711 for an extended duration of action, with the potential to move from weekly to monthly dosing. A once-monthly option could improve adherence and convenience while maintaining the efficacy expected from this class.
Preclinical Promise
Early signals of a differentiated profile
In our preclinical studies, BFRx3711 has shown an extended half-life, meaningful weight reduction, and durable glucose control, alongside a favorable regulatory profile as a small peptide. Detailed data are available to qualified partners under NDA.
Our Science
From molecular design to a defined clinical path
BFRx3711 is built around our own science — engineered in-house for stability, receptor potency, and the extended duration of action that makes less-frequent dosing possible.
Peptide Engineering & Design
We design GLP-1 peptide modifications that improve enzyme (DPP-4 and other) resistance and strengthen albumin binding — the engineering behind BFRx3711's extended half-life and once-monthly dosing ambition.
Preclinical Development
Receptor pharmacology, PK/PD characterization, and in vivo efficacy studies build the data package that de-risks a candidate. BFRx3711 has shown receptor activity comparable to semaglutide with materially extended preclinical PK.
Regulatory & CMC Strategy
We chart the path to IND and beyond. BFRx3711's short peptide profile (under 40 amino acids) is intended to support a simpler manufacturing and regulatory route relative to longer-peptide comparators.
Development to Launch
A staged roadmap through IND, Phase 1–3, and NDA, with the option to advance the program independently or alongside a strategic development partner.
Global GLP-1 sales projected above
$200B+
One of the fastest-growing segments in pharmaceuticals.
A Large and Growing Market
A differentiated dosing option in a high-growth class
GLP-1 therapies are among the fastest-growing segments in pharmaceuticals, with global sales projected above $200 billion. A differentiated, less-frequent dosing option is a compelling opportunity within that market.
Partner With Us
Begin a confidential discussion
BioFutureRx is seeking a strategic partner to advance BFRx3711. The full data package, financial model, and the identity of the asset and its originating company are available under NDA. Contact us to begin a confidential discussion.
Forward-looking statements: This page contains forward-looking statements regarding a product candidate in development. Preclinical results are not necessarily predictive of clinical outcomes, and there is no guarantee that BFRx3711 will achieve the results described or obtain regulatory approval. “BFRx3711” is a placeholder designation; the actual product and company identities are disclosed only under a non-disclosure agreement. Nothing on this page is an offer to sell or a solicitation of an offer to buy any security.